GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
|Slideshows|November 13, 2019
Treating Bipolar Depression With Atypical Antipsychotics: Pros, Cons, and Tips
Author(s)Chris Aiken, MD
Depression predominates across the lifespan in patients with bipolar disorder. Here: A discussion about (and beyond) the four FDA-approved drugs to treat symptoms.
Advertisement
Advertisement
Related to this article
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Phase 2 data show RAP-219 eases acute bipolar mania with significant YMRS gains and encouraging tolerability, setting the stage for FDA talks and phase 3 plans.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
4
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
5